{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:35:58Z","timestamp":1791293758591,"version":"4.1.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","id.theclinics.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.idc.2016.02.009","type":"journal-article","created":{"date-parts":[[2016,5,19]],"date-time":"2016-05-19T09:00:09Z","timestamp":1463648409000},"page":"491-507","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Bacteremia due to Methicillin-Resistant Staphylococcus aureus"],"prefix":"10.1016","volume":"30","author":[{"given":"Marisa","family":"Holubar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stan","family":"Deresinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.idc.2016.02.009_bib1","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1001\/jama.2014.6364","article-title":"Association between vancomycin minimum inhibitory concentration and mortality among patients with Staphylococcus aureus bloodstream infections","volume":"312","author":"Kalil","year":"2014","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.idc.2016.02.009_bib2","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1093\/cid\/ciu183","article-title":"Effect of vancomycin minimal inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus endocarditis","volume":"58","author":"Cervera","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2016.02.009_bib3","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1128\/AAC.01653-13","article-title":"Are vancomycin trough concentrations adequate for optimal dosing?","volume":"58","author":"Neely","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.idc.2016.02.009_bib4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ijantimicag.2012.10.015","article-title":"Vancomycin pharmacodynamics and survival in patients with methicillin-resistant Staphylococcus aureus-associated septic shock","volume":"41","author":"Zelenitsky","year":"2013","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"10.1016\/j.idc.2016.02.009_bib5","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2165\/11534440-000000000-00000","article-title":"New lipoglycopeptides","volume":"70","author":"Zhanel","year":"2010","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.idc.2016.02.009_bib6","doi-asserted-by":"crossref","first-page":"5007","DOI":"10.1128\/AAC.00274-15","article-title":"In\u00a0vitro activity of dalbavancin against drug resistant Staphylococcus aureus from a global surveillance program","volume":"59","author":"McCurdy","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2016.02.009_bib7","unstructured":"Dunne M, Puttagunta S. Clearance of Staphylococcus aureus bacteremia in patients treated with dalbavancin. Poster session presented at: IDWeek 2013, October 2\u20136; San Francisco, CA."},{"key":"10.1016\/j.idc.2016.02.009_bib8","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/cid\/ciu971","article-title":"Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureus","volume":"60","author":"Corey","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2016.02.009_bib9","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3109\/00365548.2014.995696","article-title":"Telavancin for refractory methicillin-resistant Staphylococcus aureus bacteremia and infective endocarditis","volume":"47","author":"Ruggero","year":"2015","journal-title":"Infect Dis (Lond)"},{"key":"10.1016\/j.idc.2016.02.009_bib10","unstructured":"Theravance Biopharma Antibiotics, Inc. A phase 3 telavancin Staphylococcus aureus bacteremia trial. NCT02208063 [Internet]. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02208063. Accessed June 30, 2015."},{"issue":"12","key":"10.1016\/j.idc.2016.02.009_bib11","doi-asserted-by":"crossref","first-page":"7462","DOI":"10.1128\/AAC.03422-14","article-title":"Heterogeneity of mprF sequences in\u00a0methicillin-resistant Staphylococcus aureus clinical isolates: role in cross-resistance between daptomycin and host defense antimicrobial peptides","volume":"58","author":"Bayer","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.idc.2016.02.009_bib12","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1749-6632.2012.06819.x","article-title":"Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall","volume":"1277","author":"Bayer","year":"2013","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"10.1016\/j.idc.2016.02.009_bib13","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1128\/CMR.00030-13","article-title":"A\u00a0current perspective on daptomycin for the clinical microbiologist","volume":"26","author":"Humphries","year":"2013","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"10.1016\/j.idc.2016.02.009_bib14","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.diagmicrobio.2015.06.003","article-title":"Duration of prior vancomycin therapy and subsequent daptomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteremia","volume":"83","author":"Culshaw","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2016.02.009_bib15","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2016.02.009_bib16","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1093\/jac\/dkt396","article-title":"Emergence of resistance to daptomycin in a cohort of patients with methicillin-resistant Staphylococcus aureus persistent bacteraemia treated with daptomycin","volume":"69","author":"Gasch","year":"2014","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.idc.2016.02.009_bib17","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ijantimicag.2010.07.011","article-title":"High-dose daptomycin in documented Staphylococcus aureus infections","volume":"36","author":"Bassetti","year":"2010","journal-title":"Int J Antimicrob Agents"},{"issue":"12","key":"10.1016\/j.idc.2016.02.009_bib18","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1093\/jac\/dkt294","article-title":"A\u00a0multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis","volume":"68","author":"Kullar","year":"2013","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"11","key":"10.1016\/j.idc.2016.02.009_bib19","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/cid\/cit112","article-title":"Early use of daptomycin versus vancomycin for methicillin-resistant staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg\/L: A matched cohort study","volume":"56","author":"Murray","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"42","key":"10.1016\/j.idc.2016.02.009_bib20","doi-asserted-by":"crossref","first-page":"16808","DOI":"10.1073\/pnas.1300118110","article-title":"How allosteric control of Staphylococcus aureus penicillin binding protein 2a enables methicillin resistance and physiological function","volume":"110","author":"Otero","year":"2013","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"7","key":"10.1016\/j.idc.2016.02.009_bib21","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1093\/jac\/dkv076","article-title":"Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009-13)","volume":"70","author":"Sader","year":"2015","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.idc.2016.02.009_bib22","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/jac\/dku455","article-title":"Ceftaroline fosamil salvage therapy: an option for reduced-vancomycin-susceptible MRSA bacteraemia","volume":"70","author":"Espedido","year":"2014","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.idc.2016.02.009_bib23","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1128\/AAC.01386-12","article-title":"Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in\u00a0vitro pharmacokinetic model of infection","volume":"57","author":"MacGowan","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 4","key":"10.1016\/j.idc.2016.02.009_bib24","first-page":"iv33","article-title":"Pharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: rationale for improved anti-methicillin-resistant Staphylococcus aureus activity","volume":"65","author":"Drusano","year":"2010","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.idc.2016.02.009_bib25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/phar.1681","article-title":"Pharmacokinetic and pharmacodynamic analyses of ceftaroline in adults with cystic fibrosis","volume":"36","author":"Autry","year":"2016","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.idc.2016.02.009_bib26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/IPC.0000000000000191","article-title":"Ceftaroline fosamil for the treatment of Staphylococcus aureus bacteremia secondary to acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia","volume":"23","author":"Vazquez","year":"2015","journal-title":"Infect Dis Clin Pract"},{"issue":"5","key":"10.1016\/j.idc.2016.02.009_bib27","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1128\/AAC.02371-13","article-title":"Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy","volume":"58","author":"Casapao","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.idc.2016.02.009_bib28","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ijantimicag.2014.07.024","article-title":"Use of ceftaroline after glycopeptide failure to eradicate meticillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations","volume":"44","author":"Paladino","year":"2014","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"10.1016\/j.idc.2016.02.009_bib29","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ijantimicag.2013.07.005","article-title":"Ceftaroline for meticillin-resistant Staphylococcus aureus bacteraemia: case series and review of the literature","volume":"42","author":"Polenakovik","year":"2013","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"10.1016\/j.idc.2016.02.009_bib30","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/jac\/dks006","article-title":"Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy","volume":"67","author":"Ho","year":"2012","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.idc.2016.02.009_bib31","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s10156-012-0449-9","article-title":"The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients","volume":"19","author":"Lin","year":"2013","journal-title":"J\u00a0Infect Chemother"},{"issue":"7","key":"10.1016\/j.idc.2016.02.009_bib32","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/jac\/dku085","article-title":"Salvage treatment of methicillin-resistant staphylococcal endocarditis with ceftaroline: a multicentre observational study","volume":"69","author":"Tattevin","year":"2014","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"11","key":"10.1016\/j.idc.2016.02.009_bib33","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/phar.1491","article-title":"Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistance","volume":"34","author":"Rybak","year":"2014","journal-title":"Pharmacotherapy"},{"issue":"4","key":"10.1016\/j.idc.2016.02.009_bib34","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.diagmicrobio.2014.12.009","article-title":"In\u00a0vitro activity of linezolid as assessed through the 2013 LEADER surveillance program","volume":"81","author":"Flamm","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"8","key":"10.1016\/j.idc.2016.02.009_bib35","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1093\/cid\/civ501","article-title":"Tedizolid: the first once daily oxazoidinone class antibiotic","volume":"61","author":"Burdette","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2016.02.009_bib36","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/jac\/dki355","article-title":"Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies","volume":"56","author":"Shorr","year":"2005","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.idc.2016.02.009_bib37","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1086\/595686","article-title":"Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study","volume":"48","author":"Wilcox","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2016.02.009_bib38","first-page":"505","article-title":"Efficacy of linezolid-based salvage therapy compared with glycopeptide-based therapy in patients with persistent methicillin-resistant Staphylococcus aureus bacteremia","volume":"65","author":"Park","year":"2012","journal-title":"J\u00a0Infect"},{"issue":"6","key":"10.1016\/j.idc.2016.02.009_bib39","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1128\/AAC.04376-14","article-title":"Comparative efficacy of tedizolid phosphate (prodrug of tedizolid), vancomycin and daptomycin in a rabbit model of methicillin-resistant Staphylococcus aureus endocarditis","volume":"59","author":"Chan","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.idc.2016.02.009_bib40","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1128\/MMBR.65.2.232-260.2001","article-title":"Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance","volume":"65","author":"Chopra","year":"2001","journal-title":"Microbiol Mol Biol Rev"},{"issue":"4","key":"10.1016\/j.idc.2016.02.009_bib41","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.diagmicrobio.2012.12.004","article-title":"Tigecycline: an update","volume":"75","author":"Stein","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2016.02.009_bib42","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1086\/648720","article-title":"Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials","volume":"50","author":"Gardiner","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2016.02.009_bib43","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/jac\/dku378","article-title":"The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA","volume":"70","author":"Barber","year":"2015","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.idc.2016.02.009_bib44","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1128\/AAC.01204-13","article-title":"\u03b2-Lactams enhance vancomycin activity against methicillin-resistant Staphylococcus aureus bacteremia compared to vancomycin alone","volume":"58","author":"Dilworth","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.idc.2016.02.009_bib45","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/jac\/dku322","article-title":"Vancomycin plus ceftaroline shows potent in\u00a0vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemia","volume":"70","author":"Barber","year":"2015","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.idc.2016.02.009_bib46","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/cid\/civ808","article-title":"Combination of Vancomycin and \u03b2-Lactam Therapy for Methicillin-Resistant Staphylococcus aureus Bacteremia: A Pilot Multicenter Randomized Controlled Trial","volume":"62","author":"Davis","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.idc.2016.02.009_bib47","doi-asserted-by":"crossref","first-page":"734","DOI":"10.4161\/viru.26909","article-title":"Vancomycin monotherapy vs. combination therapy for the treatment of persistent methicillin-resistant Staphylococcus aureus bacteremia","volume":"4","author":"Seah","year":"2013","journal-title":"Virulence"},{"issue":"3","key":"10.1016\/j.idc.2016.02.009_bib48","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1086\/600295","article-title":"Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem","volume":"49","author":"Jang","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.idc.2016.02.009_bib49","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1128\/AAC.00594-13","article-title":"\u03b2-Lactam antibiotics targeting PBP1 selectively enhance daptomycin activity against methicillin-resistant Staphylococcus aureus","volume":"57","author":"Berti","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.idc.2016.02.009_bib50","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1128\/AAC.00502-12","article-title":"Altering the proclivity towards daptomycin resistance in methicillin-resistant Staphylococcus aureus using combinations with other antibiotics","volume":"56","author":"Berti","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.idc.2016.02.009_bib51","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1128\/AAC.02192-12","article-title":"Multicenter evaluation of the clinical outcomes of daptomycin with and without concomitant \u03b2-lactams in patients with Staphylococcus aureus bacteremia and mild to moderate renal impairment","volume":"57","author":"Moise","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.idc.2016.02.009_bib52","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/j.clinthera.2009.09.012","article-title":"Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin\u00ae Outcomes Registry and Experience","volume":"31","author":"Sakoulas","year":"2009","journal-title":"Clin Ther"},{"issue":"10","key":"10.1016\/j.idc.2016.02.009_bib53","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.clinthera.2014.09.005","article-title":"Daptomycin in combination with other antibiotics for the treatment of complicated methicillin-resistant Staphylococcus aureus bacteremia","volume":"36","author":"Dhand","year":"2014","journal-title":"Clin Ther"},{"key":"10.1016\/j.idc.2016.02.009_bib54","doi-asserted-by":"crossref","first-page":"h2219","DOI":"10.1136\/bmj.h2219","article-title":"Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: randomised controlled trial","volume":"350","author":"Paul","year":"2015","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.idc.2016.02.009_bib55","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1128\/AAC.04141-14","article-title":"Impact of the combination of daptomycin and trimethoprim-sulfamethoxazole on clinical outcomes in methicillin-resistant Staphylococcus aureus infections","volume":"59","author":"Claeys","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2016.02.009_bib56","unstructured":"Zasowski E, Claeys K, Roberts K. Retrospective evaluation of daptomycin (DAP) plus ceftaroline fosamil (CPT) versus DAP plus sulfamethoxazole\/trimethoprim (SMX\/TMP) for methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSI). Presented in poster session at the 25th European Congress of Clincial Microbiology and Infectious Diseases (ECCMID), Copenhagen, Denmark, April 25 \u2013 28, 2015."},{"issue":"2","key":"10.1016\/j.idc.2016.02.009_bib57","doi-asserted-by":"crossref","first-page":"ofu046","DOI":"10.1093\/ofid\/ofu046","article-title":"Ceftaroline in combination with trimethoprim-sulfamethoxazole for salvage therapy of methicillin-resistant Staphylococcus aureus bacteremia and endocarditis","volume":"1","author":"Fabre","year":"2014","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"10.1016\/j.idc.2016.02.009_bib58","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1128\/AAC.06449-11","article-title":"High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis","volume":"56","author":"Mi\u0155o","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.idc.2016.02.009_bib59","first-page":"960","article-title":"Successful management of methicillin-resistant Staphylococcus aureus bacteremia unresponsive to Vancomycin by adding fosfomycin: a case report","volume":"95","author":"Linasmita","year":"2012","journal-title":"J\u00a0Med Assoc Thai"},{"issue":"8","key":"10.1016\/j.idc.2016.02.009_bib60","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1093\/cid\/ciu580","article-title":"Efficacy and safety of fosfomycin plus imipenem as rescue therapy for complicated bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: a multicenter clinical trial","volume":"59","author":"Del Rio","year":"2014","journal-title":"Clin Infect Dis"}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552016300150?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552016300150?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T03:19:13Z","timestamp":1656386353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891552016300150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0891552016300150"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2016.02.009","relation":{},"ISSN":["0891-5520"],"issn-type":[{"value":"0891-5520","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bacteremia due to Methicillin-Resistant Staphylococcus aureus","name":"articletitle","label":"Article Title"},{"value":"Infectious Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idc.2016.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}